Amazon.com: Anxiolytic Compounds: Perspectives in Drug Development (9780471957133): Neal R. Cutler, John J. Sramek, Neil M. Kurtz: Books

Have one to sell? Sell yours here
Anxiolytic Compounds: Perspectives in Drug Development
 
 
Tell the Publisher!
I'd like to read this book on Kindle

Don't have a Kindle? Get your Kindle here, or download a FREE Kindle Reading App.

Anxiolytic Compounds: Perspectives in Drug Development [Hardcover]

Neal R. Cutler (Author), John J. Sramek (Author), Neil M. Kurtz (Author)


Available from these sellers.


Textbook Student FREE Two-Day Shipping for students on millions of items. Learn more


Book Description

June 5, 1996 0471957135 978-0471957133 1
In the exciting and rapidly expanding field of drug development, there is an emphasis on the clear delineation of psychiatric symptoms, syndromes and disorders, and disorders, and improved strategies for making diagnoses. Here the authors concentrate on the anxiolytics, a group of drugs which must be evaluated in carefully defined groups of patients using sensitive outcome measures. Efficacy is not always easy to establish and large clinical trials are needed to verify effectiveness of the drug, the degree of efficacy and the risks of unwanted effects. Conducting these trials is not an easy matter and this timely, critical and comprehensive guide aims to provide awareness of the major issues surrounding development of anxiolytics and, in particular, details of the techniques needed to assess new and hopefully improved therapies. This book, written by authors well known for their extensive experience in the field of drug development, will be of interest to the academic community frequently involved in clinical trials of potential anxiolytic compounds, as well as to the pharmaceutical industry in the formulation of drug development programmes for new anxiolytics.

Editorial Reviews

From the Publisher

The authors concentrate on the anxiolytics, a group of drugs which must be evaluated in carefully-defined groups of patients using sensitive outcome measures. But efficacy is not always easy to establish and large clinical trials are needed to verify effectiveness of the drug, the degree of efficacy, and the risks of unwanted effects. Conducting these trials is not always an easy matter, and this timely, critical and comprehensive guide aims to provide awareness of the major issues surrounding development of anxiolytics and, in particular, details of the techniques needed to assess new and hopefully improved therapies.

Product Details

  • Hardcover: 176 pages
  • Publisher: John Wiley & Sons; 1 edition (June 5, 1996)
  • Language: English
  • ISBN-10: 0471957135
  • ISBN-13: 978-0471957133
  • Product Dimensions: 9.2 x 6.4 x 0.6 inches
  • Shipping Weight: 13.6 ounces
  • Amazon Best Sellers Rank: #5,817,557 in Books (See Top 100 in Books)

More About the Author

Discover books, learn about writers, read author blogs, and more.

Customer Reviews


There are no customer reviews yet.
Video reviews
Video reviews
Amazon now allows customers to upload product video reviews. Use a webcam or video camera to record and upload reviews to Amazon.



Tag this product

 (What's this?)
Think of a tag as a keyword or label you consider is strongly related to this product.
Tags will help all customers organize and find favorite items.
Your tags: Add your first tag
 

Sell a Digital Version of This Book in the Kindle Store

If you are a publisher or author and hold the digital rights to a book, you can sell a digital version of it in our Kindle Store. Learn more

Customer Discussions

This product's forum
Discussion Replies Latest Post
No discussions yet

Ask questions, Share opinions, Gain insight
Start a new discussion
Topic:
First post:
Prompts for sign-in
 


Active discussions in related forums
Search Customer Discussions
Search all Amazon discussions
   
Related forums


Listmania!


Create a Listmania! list

So You'd Like to...


Create a guide


Look for Similar Items by Category


Look for Similar Items by Subject